Диссертация (1140690), страница 25
Текст из файла (страница 25)
Eastell [et al.] // J. Intern. Med. – 1998. – № 244. – P. 271292.99.Abundat calcitonin receptors in isolated osteoclasts / G. C. Nicholson [etal.] // J. Clin. Invest. – 1986. – № 78. – P. 355-360.100.Adverse events reported by postmenopausal women in controlled trialswith raloxifene / G. C. Davies [et al.] // Obstet.
Gynecol. – 1999. – Vol. 93, №. 4 – P.558-565.101.Altered mineral metabolism in glococorticoid-indiced osteopenia: effect of25-hydroxyvitamin D administration / T. J. Hahn [et al] // J. Clin. Invest. – 1979. – №64. – P. 655-665.102.American association of endocrinologists (AACE) medical guidelines forthe prevention and treatment of postmenopausal osteoporosis: 2001 edition, withselected updates for 2003 // Endocrine Practice. – 2003. – Vol. 9, № 6. – P. 544-564.103.Amin, S. Osteoporosis in men / S.
Amin, D. T. Felson // Osteoporos Int. –2001. – № 27. – P. 19-47.104.Analgesic effect of salmon calcitonin suppositories in patients with acutepain due to recent osteoporotic vertebral crush fractures: a prospective double-blind,randomized, placebo-controlled clinical study / G. P. Lyritis [et al.] // Clin. J. Pain. –1999. – Vol. 15, № 4. – P. 284-289.105.Anandarajian, A. P. Role of RANKL in bone deseases / A. P. Anandarajian// Trends Epidemiol Metab. – 2008. – Vol.
20, № 2. – P. 88-94.158106.Arnett, T. R. A comparative study of disaggregated chick and ratosteoclasts in vitro: effects of calcitonin and prostaglandins / T. R. Arnett, D. W.Demster // Endocrinology. – 1994. – № 135. – P. 183-190.107.Avian osteoclasts as estrogen target cells / Oursler M. J. [et al.] // Proc.Natl. Acad. Sci.
USA. – 1991. – № 88. – P. 6613-6617.108.Baron, R. Importance of the intermediate phases between resorption andformation in the measurement and understanding of the bone remodeling sequence / R.Baron // Bone histomorphometry: proceedings of the second international workshop /ed. P. J. Meunier.
– Toulouse : Societe de la Nouvelle Imprimerie Foumic, 1977. – P.179-183.109.Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday /M. McClung [et al.] // Am. J. Med. – 2013. – Vol. 126. – P. 13-20.110.Bone mineral density in increased following monthly administration ofAMG 162 in cynomologus monkeys / L. F.
Atkinsos [et al.] // J. Bone Mineral Res. –2003. – № 18. – P. 596.111.Bovenzi, M. Low back pain disorders and exposure to whole-bodyvibration in the workplace / M. Bovenzi // Semin. Perinatol. – 1996. – Vol. 20, № 1. –P. 38-53.112.Bovenzi, M. Prevalence of vibration-induced white finger and assessementof vibration exposure among travertine workers in Italy / M. Bovenzi, A. Franzinelli, F.Strambi // Ind. Arch. Occup.
Environ Health. – 1990. – Vol. 61, № l/2. – P. 25-34.113.Bowman, A. R. Drug and hormone effects on vitamin D metabolism / A. R.Bowman, S. Epstein // Vitamin D / eds.: D. Feldman, F. H. Glorieux, J. W. Pike. – SanDiego: Academic Press, 1997. – P. 797-829.114.Breslau, N.
A. Pharmacology of vitamin D preparations / N. A. Breslau, J.F Zervech // Vitamin D / eds.: D. Feldman, F. H. Glorieux, J. W. Pike. – San Diego:Academic Press, 1997. – P. 607-618.115.Brown, J. P. Clinical practice guidelines for the diagnosis and managementof osteoporosis in Canada / J. P. Brown, R. G. Josse // CMAJ. – 2002. – Vol. 167,suppl. 10. – P.
S1-S34.159116.Chonchol, M. 25-hydroxyvitamin D, insulin resistance, and kidney fictionin the Third National Health and Nutrition Examination Survey / M. Chonchol, R.Scragg // Kidney Int. – 2007. – Vol. 71, № 2. – P. 134-139.117.Clinical features of the hand-arm vibration syndrome in miners / T. Kakosy[et al.] // Orv. Hetil. – 2006.
– Vol. 147, № 18. – P. 833-839.118.Clinical use of teriparatide in the real world: initial insights / P. D. Miller[et al.] // J. Endocrine Practice. – 2004. – Vol. 10. – P. 139-148.119.Comparative effects on bone mineral density of tibolone, transdermalestrogen and oral estrogen\progestagen therapy in postmenopausal women / G. M.Prelevic [et al.] // Gynecol. Endocrinol. – 1993. – № 6. – P.
413-420.120.Comparison of effects of Alfacalcidol and Cholecalciferol on bone andcalcium metabolism in ovariectomized rats / S. Takeda [et al.] // J. Bone Miner. Res. –1997. – № 12, suppl. 1. – P. 356.121.Coxon, F. P. Recent advances in understanding the mechanism of action ofbisphosphonates / F. P.Coxon, K. Thompson, M.
G. Rogers // Curr. Opin. Phgormacol.– 2006. – № 6. – P. 307-312.122.Cytosolic entry of bisphosphonate drugs requires acidification of vesiclesafter fluid-phase endocytosis / K. Thompson [et al.] // Mol. Pharmacol. – 2006. – № 69.– P. 1624-1632.123.Dahlin, L. B. Vibration-induced hand problems: role of the peripheralnerves in the pathophysiology / L.
B. Dahlin, G. Lundborg // Scand. J. Plast. Reconstr.Surg. Hand Surg. – 2001. – Vol. 35, № 3. – P. 225-232.124.Delany, A. M. Cortisol downregulates osteoblast alpha 1 (I) procollagenmRNA by transcriptional and posttranscriptional mechanisms / A. M. Delany, B. Y.Gabbitas, E. Canalis // J. Cell. Biochem. – 1995.
– № 57, suppl. 3. – P. 488-494.125.Delany, A. M. Mechanism of glucocorticoid action in bone cells / A. M.Delany, Y. Dong, E. Canalis // J. Cell. Biochem. – 1994. – № 56, suppl. 3. – P. 295-302.126.Dempster, D. W. Bone remodeling / D. W. Dempster // Disorders of boneand mineral metabolism / eds.: F.
L. Coe, M. J. Favus. – New York : Raven Press, 1992.– P.355-380.160127.Dempster, D. W. Distinguishing effects between antiresorptive andanabolic therapies / D. W. Dempster // The Changing Treatment of Osteororosis.Incorporating Anabolic Therapy: abstracts of Satellite Symposium of Fifth InternationalSymposium: Clinical Advances in Osteoporosis. – Honolulu, 2002. – P. 7-12.128.Denosumab (AMG 162, a fully human RANKL antibody), increasescortical ond cancellous bone mass and density in aged ovariectomised cynamologusmonkeys / M.
Ominsky [et al.] // J. Bone Mineral Res. – 2006. – № 21. – P. S72.129.forDiagnosis and Treatment of Osteoporosis: Health Care Guideline / InstituteClinicalSystemImprovement(ICSI)[Electronicresource]–URL:http://www.guideline.gov/content.aspx?id=47543 (дата обращения: 14.01.2015).130.Early effects of raloxifene on clinical vertebral fracture at 12 months inpostmenopausal women with osteoporosis / M. Maricic [et al.] // Arch. Intern. Med. –2002.
– Vol. 162, № 10. – P. 1140-1143.131.Effect of calcium and vitamin D supplementation on blood pressure: thewomen’s health initiative randomized trial / K. L. Margolis [et al.] // Hypertension. –2008. – Vol. 52, № 5. – P. 847-855.132.Effect of daily hormone therapy and alendronate use on bone mineraldensity in postmenopausal women / I. Davas [et al.] // Fertil. Steril. – 2003. – Vol. 80. –P. 536-540.133.Effect of discontinuation of estrogen, calcitriol, and the combination ofboth on bone density and bone markers / C.
J. Galladgher [et al.] // J. of ClinicalEndocrinol. Metabolism. – 2002. – Vol. 87, № 11 – P. 4914-4923.134.Effect of glucocorticoids on function of the parathyroid glnds in man / R. F.Fucik [et al.] // J. Clin Endocrinol Metab. – 1975. – № 10.
– P. 152-155.135.Effect of osteoporosis treatment on mortality: a meta-analysis / M. J.Bolland [et al.] // J. Clin. Endocrinol. Metab. – 2010. – Vol. 95. – P. 1174-1181.136.Effect of raloxifene on bone mineral density and biochemical markers ofbone turnover in Japanese postmenopausal women with osteoporosis: results fromfandomized placebo-controlled trial / H. Morii [et al.] // Osteoporos Int. – 2003. – Vol.14, № 10. – P. 793-800.161137.Effects of cyclical etidronatecombinated with calcitriol versuscyclicalethidronate aloneon spine and femoral neckbone mineral density in postmenopausalosteoporotic women / T. Masud [et al.] // Ann. Rheum.
Dis. – 1998. – № 58. – P. 346349.138.Effects of raloxifene on bone mineral density, serum cholesterolconcentrations and uterine endometrium in postmenopausal women / P. D. Delmas [etal.] // New Engl. J. Med. – 1997. – Vol. 337, № 23 – P.1641-1647.139.Egan, J. J. Parathyroid hormone promotes the disassembly of cytosceletalactin and myosin in cultured osteoblastic cells: mediation by cyclic AMP / J.
J. Egan, G.Gronowicz, G. A. Rodan // J. Cell Biochem. – 1991. – № 45. – P. 101-111.140.Evidence of estrogen receptors in normal human osteoblast-like cells / E. F.Eriksen [et al.] // Science. – 1988. – № 241. – P. 84-86.141.Fisher, J.
E. In vivo effects of bisphosphonates on the osteoclastmevalonate pathway / J. E. Fisher, G. A. Rodan, A. A. Reszka // Endocrinology. – 2000.– № 141. – P. 4793-4796.142.Frost, H. M. Intermediary organization of the skeleton / Harold M. Frost. –Boca Raton, FL: CRC Press, 1986. – Vol. 2 : Human skeleton. – 352 p.143.Gallagher, J. C.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
